Sign in

You're signed outSign in or to get full access.

GC

GERON CORP (GERN)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 net product revenue was $47.5M, bringing total 2024 net revenue to $77.0M and net product revenue since launch to $76.5M; net loss was $25.4M ($0.04 EPS). Management noted Q3 and Q4 revenues “exceeded our expectations.”
  • Revenue trajectory slowed in recent months due to flat new patient starts, with week-over-week variability but 4–8 week averages flat into January/February; management is not providing revenue guidance yet.
  • 2025 OpEx guidance: $270–$285M; management expects to reach profitability without additional financing if internal sales and OpEx expectations are met.
  • EU path advanced: CHMP positive opinion in Dec-2024; the European Commission subsequently granted approval on Mar 11, 2025 (post-quarter). These support medium-term international expansion planning for 2026 launches.

What Went Well and What Went Wrong

What Went Well

  • “In the fourth quarter of 2024… we achieved $47.5 million in RYTELO net product revenue. Since product availability at the end of June 2024 and through year-end, we achieved $76.5 million in net product revenue, which exceeded our internal expectations.”
  • Payer access established: “Payers responsible for approximately 80% of the U.S. covered lives have implemented medical coverage policies for Rytelo, consistent with the FDA label… and/or NCCN guidelines.”
  • Strategic positioning: Management reiterated “blockbuster potential” and highlighted RS-negative second-line opportunity, with potential to achieve blockbuster status treating ~1/3 of eligible U.S. patients.

What Went Wrong

  • New patient starts flat over the past few months; duration appears consistent with IMerge median (~8 months), but second-line starts were lower than expectations, concentrating uptake in third-line+.
  • Launch seasonality: Hesitancy to start monitored therapies around holidays (Thanksgiving) contributed to flatness, with trends highly correlated to the primary competitor.
  • MF timeline pushed: IMpactMF interim analysis moved from “early 2026” to “2H 2026”; final moved from “early 2027” to “2H 2028,” prolonging a key potential growth catalyst.

Financial Results

Summary Financials (USD)

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Total Net Revenue ($MM)$0.023 $0.882 $28.271 $47.538
Net Product Revenue ($MM)$0.000 $0.780 $28.209 $47.507
Net Loss ($MM)$(51.974) $(67.383) $(26.447) $(25.352)
Diluted EPS ($)$(0.09) $(0.10) $(0.04) $(0.04)
Total Operating Expenses ($MM)$54.312 $70.215 $56.486 $67.587

Margins

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Gross Margin %N/A (no COGS) 98.1% [(0.882−0.017)/0.882] 98.4% [(28.271−0.456)/28.271] 98.4% [(47.538−0.783)/47.538]
Net Income Margin %(2260.5%) [−51.974/0.023] (7650.3%) [−67.383/0.882] (93.6%) [−26.447/28.271] (53.3%) [−25.352/47.538]

Segment/Revenue Component Breakdown

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Net Product Revenue ($MM)$0.000 $0.780 $28.209 $47.507
Royalties ($MM)$0.023 $0.102 $0.062 $0.031

KPIs and Operating Metrics

MetricQ4 2023Q2 2024Q3 2024Q4 2024
Cost of Goods Sold ($MM)— $0.017 $0.456 $0.783
Cash + Mkt Securities ($MM)N/A≈$430.4 ≈$378.9 (as of 9/30/24) ≈$502.9
IMpactMF Enrollment (%)N/A~70% (Aug 2024) N/A~80%
Payer Coverage (% U.S. covered lives)N/AN/AN/A≈80%

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Total Operating ExpensesFY 2025Not previously provided$270–$285M New
Profitability ExpectationFY 2025Not previously providedExpect profitability without additional financing if internal sales/OpEx met New
IMpactMF Interim Analysis TimingMF TrialEarly 2026 2H 2026 Delayed
IMpactMF Final Analysis TimingMF TrialEarly 2027 2H 2028 Delayed
EU Approval (RYTELO)LR-MDS (EU)CHMP positive opinion; EC decision expected H1 2025 EC approval granted Mar 11, 2025 Approved (post-quarter)
Revenue GuidanceFY 2025N/ANot providing revenue guidance yet Maintained (no guidance)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3 2024)Current Period (Q4 2024)Trend
Launch uptake/revenueEarly success: ≈160 patients by Jul 31; initial revenue ~$0.78M (partial quarter). Net product revenue $47.5M in Q4; total since launch $76.5M; Q3/Q4 exceeded internal expectations. Strong absolute growth; momentum slowed recently
Payer accessN/A (Q2/Q3)Policies covering ≈80% of U.S. lives implemented, consistent with label/guidelines. Broadening access supports adoption
Seasonality/New startsN/ANew patient starts flat since Thanksgiving; high correlation with competitor trend; focus to drive earlier-line use. Seasonal softness; execution plan in place
RS-negative focusNCCN Category 1 (2L) & 2A (1L ESA-ineligible). Refining messaging/segmentation to sharpen RS-negative differentiation. Targeted push into RS-negative 2L
EU regulatoryCHMP positive opinion; EC decision expected H1’25. EC approval (Mar 11, 2025). Regulatory progress; EU launch planning for 2026
MF program timingInterim “early 2026”; final “early 2027.” Interim “2H 2026”; final “2H 2028.” Timelines extended
Financing/liquidity$125M Royalty Pharma + up to $250M Pharmakon; pro forma liquidity ~$542.4M; repaid Hercules debt. YE cash + securities ~$502.9M; higher interest expense partly from Royalty Pharma/debt. Strong liquidity; higher interest expense

Management Commentary

  • “2024 was a terrific year for Geron and for RYTELO… Q3 and Q4 revenues exceeded our expectations.” — John Scarlett, CEO
  • “We achieved $47.5 million in Rytelo net product revenue [Q4]… $76.5 million since product availability at the end of June 2024.” — John Scarlett
  • “Payers responsible for approximately 80% of the U.S. covered lives have implemented medical coverage policies for Rytelo.” — Jim Ziegler, CCO
  • “Our priority is to drive new patient starts… particularly ESA relapsed/refractory RS-negative patients… where Rytelo’s benefit are notably differentiated.” — Jim Ziegler
  • “We expect to reach profitability without additional financing if our current internal sales and operating expense expectations are met.” — Michelle Robertson, CFO

Q&A Highlights

  • Revenue trajectory: 4–8 week rolling averages were flat into January/February; too early to call Q1 revenue; no FY25 revenue guidance yet; OpEx guide intact with spend reallocation flexibility.
  • Seasonality and adoption: Launch seasonality around holidays dampened starts; plan to increase reach/frequency and share of voice to drive earlier-line adoption.
  • New patient starts vs duration: Duration not the issue (approaching IMerge median); softness driven by starts; focus on converting beyond early adopters.
  • RS-negative emphasis and sequencing: Utilization across RS-positive/negative and lines; sharpening differentiation in RS-negative second-line; many starts currently third-line+.
  • Strategic focus: 90%+ near-term focus on U.S. commercial execution before broader ex-U.S. expansion (EU commercialization prep underway).

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 2024 EPS and revenue was unavailable at time of analysis due to an S&P Global access limitation; as a result, beat/miss vs consensus cannot be assessed here. Values retrieved from S&P Global were unavailable.
  • Management indicated internal expectations were exceeded for Q3/Q4 revenues, but with recent start-rate flatness, near-term Street estimates may need to reflect a more gradual adoption curve into earlier lines.

Key Takeaways for Investors

  • Absolute revenue growth was strong in Q4 ($47.5M), but the narrative turned to execution: new starts flat, with focus on RS-negative second-line and community HCP engagement to re-accelerate trajectory.
  • Liquidity remains robust (~$503M cash/securities), and OpEx guidance implies disciplined spending; management targets profitability without additional financing contingent on execution.
  • MF catalyst timeline extension (interim 2H 2026; final 2H 2028) defers a major upside scenario, increasing reliance on LR-MDS commercial ramp near term.
  • EU approval (post-Q4) validates global opportunity; however, revenue contributions likely begin in 2026, making 2025 a U.S.-focused execution year.
  • Watch near-term indicators: earlier-line mix shift, RS-negative adoption, payer policy breadth translating to starts, and any cadence updates on growth and medical affairs publications (e.g., ASH-derived analyses).
  • Interest expense stepped up with Royalty Pharma and Pharmakon financing; monitor leverage vs growth as SG&A scales and revenue ramps.
  • Without consensus comparison, the stock likely trades on launch execution signals and narrative around accelerating new patient starts; any demonstrated earlier-line uptake would be a positive catalyst.